Adamas Pharmaceuticals Inc. (Nasdaq: ADMS) reported positive results from a Phase 3 study of its ADS-5102 to treat levodopa-induced dyskinesia associated with Parkinson's disease. The stock price leaped $9.20 to $26.06.
Adamas Pharmaceuticals reports positive study results
December 23, 2015 at 11:31 AM EST
